{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-034689","form_type":"8-K","ticker":"REVB","cik":"0001810560","company_name":"REVELATION BIOSCIENCES, INC.","filed_at":"2025-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.975104+00:00","generated_at":"2026-05-25T07:12:13.910603+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Revelation Biosciences reports FY2024 net loss of $15.0M; cash at $6.5M, expects to fund ops into 2025","bullets":["Q4 2024 net loss $1.7M ($4.98/share) vs $2.2M ($133.64/share) in Q4 2023.","FY2024 net loss $15.0M ($87.68/share) vs $0.1M ($8.44/share) in FY2023.","Cash and equivalents $6.5M at Dec 31, 2024, down from $12.0M a year ago.","Operating cash burn $18.3M in FY2024 vs $7.3M in FY2023.","Phase 1b PRIME study of Gemini in CKD patients dosing; topline data expected mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-034689","json":"https://secwatch.observer/filing/0000950170-25-034689.json","markdown":"https://secwatch.observer/filing/0000950170-25-034689.md","text":"https://secwatch.observer/filing/0000950170-25-034689.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810560/000095017025034689/0000950170-25-034689-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810560/000095017025034689/revb-20250306.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T07:12:13.910603+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}